Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: Multivariate analysis of a French multicentre study

European Journal of Surgical Oncology

Volumn 36, Issue 11, 2010, Pages 1066-1072

  Poncelet, C ^a,b   Fauvet, R ^a   Yazbeck, C ^c   Coutant, C ^a   Darai, E ^a  

^a HÔPITAL TENON   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c INSERM   (France)

Author keywords

Borderline ovarian tumors; CA125; CA15 3; CA19 9; CEA; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN 1; TUMOR MARKER;

ARTICLE; BORDERLINE OVARIAN TUMOR; CANCER STAGING; FEMALE; FOLLOW UP; FRANCE; HISTOLOGY; HUMAN; HUMAN TISSUE; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ADULT; AGED; ANALYSIS OF VARIANCE; ASCITES; BLOOD; CLINICAL TRIAL; COMPLICATION; FROZEN SECTION; LAPAROSCOPY; MIDDLE AGED; MULTICENTER STUDY; OVARIAN NEOPLASMS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; AGED; ANALYSIS OF VARIANCE; ASCITES; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; FOLLOW-UP STUDIES; FRANCE; FROZEN SECTIONS; HUMANS; LAPAROSCOPY; LAPAROTOMY; LOGISTIC MODELS; MIDDLE AGED; MUCIN-1; NEOPLASM STAGING; OVARIAN NEOPLASMS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 77957878531     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.07.004     Document Type: Article

References (34)

1. International Federation of Gynecology and Obstetrics Classification and staging of malignant tumors in the female pelvis Acta Obstet Gynecol Scand 50 1971 1 7
2. R.E. Scully World Health Organization classification and nomenclature of ovarian cancer Natl Cancer Inst 42 1975 5 7
3. D.G. Bostwick, H.D. Tazelaar, S.C. Ballon, M.R. Hendrickson, and R.L. Kempson Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases Cancer 58 1986 2052 2065
4. International Federation of Gynaecoloy and Obstetrics Annual report and results of treatment in gynaecologic cancer Int J Gynaecol Obstet 28 1989 189 190
5. S.M. Rota, G. Zanetta, and N. Ieda Clinical relevance of retroperitoneal involvement from epithelial ovarian tumors of borderline malignancy Int J Gynecol Cancer 9 1999 477 480
6. H.D. Tazelaar, D.G. Bostwick, S.C. Ballon, M.R. Hendrickson, and R.L. Kempson Conservative treatment of borderline ovarian tumors Obstet Gynecol 66 1985 417 442
7. S.K. Lim-Tan, H.E. Cajigas, and R.E. Scully Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases Obstet Gynecol 72 1988 775 781
8. P. Morice, S. Camatte, J. El Hassan, P. Pautier, P. Duvillard, and D. Castaigne Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors Fertil Steril 75 2001 92 96
9. P. Morice, S. Camatte, and F. Wicart-Poque Results of conservative management of epithelial malignant and borderline ovarian tumours Hum Reprod Update 9 2003 185 192
10. P. Morice Borderline tumours of the ovary and fertility Eur J Cancer 42 2006 149 158
11. J. Donnez, A. Munschke, and M. Berliere Safety of conservative management and fertility outcome in women with borderline tumors of the ovary Fertil Steril 79 2003 1216 1221
12. R. Fauvet, J. Boccara, C. Dufournet, E. David-Montefiore, C. Poncelet, and E. Darai Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study Cancer 100 2004 1145 1151 (Pubitemid 38325941)
13. R. Fauvet, J. Boccara, C. Dufournet, C. Poncelet, and E. Darai Laparoscopic management of borderline ovarian tumors: results of a French multicenter study Ann Oncol 16 2005 403 410 (Pubitemid 40458316)
14. R. Fauvet, C. Poncelet, J. Boccara, P. Descamps, E. Fondrinier, and E. Darai Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study Fertil Steril 83 2005 284 290 (Pubitemid 40221778)
15. C. Poncelet, R. Fauvet, J. Boccara, and E. Darai Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study Ann Surg Oncol 13 2006 565 571
16. H. Hricak MRI of the female pelvis: a review AJR 146 1986 1115 1122
17. R. Molina, B. Ojeda, and X. Filella A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas Tumour Biol 13 1992 278 286
18. K. Tamakoshi, F. Kikkawa, and K. Shibata Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor Gynecol Oncol 62 1996 67 72
19. M. Takemori, R. Nishimura, and K. Hasegawa Clinical evaluation of MRI in the diagnosis of borderline ovarian tumors Acta Obstet Gynecol Scand 81 2002 157 161
20. M. Bazot, J. Nassar-Slaba, I. Thomassin-Naggara, A. Cortez, S. Uzan, and E. Darai MR imaging compared with intraoperative frozen-section examination for the diagnosis of adnexal tumors; correlation with final histology Eur Radiol 2006 Mar 18 [Epub ahead of print]
21. D. Timmerman, B. Van Calster, and D. Jurkovic Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors J Clin Oncol 25 2007 4194 4200
22. E. Darai, J. Teboul, and F. Walker Epithelial ovarian carcinoma of low malignant potential Eur J Obstet Gyneco Reprod Biol 66 1996 141 145
23. W.H. Gottlieb, D. Soriano, and R. Achiron CA125 measurement and ultrasonography in borderline tumors of the ovary Am J Obstet Gynecol 183 2000 541 546
24. M.J. Engelen, H.W. De Bruijn, and H. Hollema Serum CA125, carcinoembryonic antigen, and CA19-9 as tumor markers in borderline ovarian tumors Gynecol Oncol 78 2000 16 20
25. G. Zanetta, S. Rota, A. Lissoni, A. Meni, G. Brancatelli, and A. Buda Ultrasound, physical examination, and CA125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors Gynecol Oncol 81 2001 63 66
26. R.C. Bast Jr., D. Badgwell, and Z. Lu New tumor markers: CA125 and beyond Int J Gynecol Cancer 15 2005 274 281
27. G.D. Malkasian Jr., R.C. Knapp, and P.T. Lavin Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease Am J Obstet Gynecol 159 1988 341 346
28. R. Moore, D. McMeekin, and A. Brown A novel multiple marker bioassay utilizing He4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol Oncol 112 2009 40 46
29. K. Huhtinen, P. Suvitie, and J. Hiissa Serum He4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cyst Br J Cancer 100 2009 1315 1319
30. M. Montagnana, G. Lippi, E. Danese, M. Franchi, and G. Guidi Usefulness of serum He4 in endometriotic cysts Br J Cancer 101 2009 548
31. A. Fagotti, F. Fanfani, and M. Ludovisi Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study Gynecol Oncol 96 2005 729 735
32. A. Maneo, M. Vignali, S. Chiari, A. Colombo, C. Mangioni, and F. Landoni Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol 94 2004 387 392
33. J.D. Seidman, and R.J. Kurman Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases Am J Surg Pathol 20 1996 1331 1345
34. G. Oskay-Oezcelik, A. du Bois, and P.A. Fasching What do patients think about CA125 monitoring in the follow-up? Results from a multicenter trial in 1 060 patients with ovarian cancer American Society of Clinical Oncology (ASCO) Meeting 2009. Abstract number 5522 JCO 27 15S 2009 282S